Quantum Biopharma Seeks FDA Clearance for Lucid-MS Phase 2 Trial
Quantum Biopharma is advancing a cannabis-based therapeutic phase 2 trial for Lucid-MS. This trial targets cognitive symptoms in multiple sclerosis patients. The phase 2 trial is a critical step to evaluate efficacy beyond safety.
Over 70% of MS Patients in Rehab Take 5+ Medications, Study Finds
Polypharmacy in MS rehabilitation is a significant clinical challenge, with over 70% of patients taking five or more medications. This study highlights the potential for cannabis to consolidate therapies and reduce drug interactions. Understanding…
MS Cases Double in England Over 20 Years; Life Expectancy Rises
Multiple sclerosis spasticity cannabis treatments are gaining attention as MS cases double in England over 20 years. Improved survival rates mean more patients live longer with chronic symptoms. Cannabis therapies offer promising options for managing…
5 Essential Breakthroughs in Cannabis Neuromodulation
5 Essential Breakthroughs in Cannabis Neuromodulation Imagine a world where a simple plant could revolutionize the way we treat some of the most challenging health issues, from anxiety and depression to Alzheimer's and Parkinson's disease.…
Recent Meta-Analysis Shows CBD’s Potential in MS Treatment
A recent meta-analysis highlights the potential of cbd treatment multiple sclerosis in reducing symptom severity and disease progression. The study found consistent evidence of CBD’s immunomodulatory effects in MS models. These findings support further…